Skip to main navigation Skip to search Skip to main content

Australian Biotechnology: A 10-Year Study of Investor Performance

    Research output: Contribution to journal › Article › peer-review

    7 Citations (Scopus)

    Abstract

    A recent study assessed the investor performance of the Australian drug development biotech (DDB) sector over a 15-year period from 2003 to 2018. The current study builds on that research and extends the analysis to 2020, using a 10-year period starting 2010, to exclude the impact of the global financial crisis in 2008/09. Based on a value-weighted portfolio of all 41 DDB firms, the overall sector delivered a negative annualized return of -4.1%. Individual firm performance was also assessed using the compound annual growth rate (CAGR) in share price over the period as a measure of investor outcomes. On this basis 68% of firms produced negative CAGRs over the period, and of the 32% of firms that produced positive CAGRs, six firms produced CAGRs greater than 20% per annum and in three cases of recently-listed firms, the CAGR's were greater than 50%. Overall however, the sector overall delivered very poor investor returns and despite a relatively large number of listed biotech firms, Australian biotechnology continues to be small and weak in terms of its contribution to global biotechnology industrialization. As such it lacks the critical mass to grow a robust bioeconomy based on drug development, which remains the standard-bearer of biotechnology industrialization.

    Original languageEnglish
    Pages (from-to)16-25
    Number of pages10
    JournalJournal of Commercial Biotechnology
    Volume26
    Issue number4
    DOIs
    Publication statusPublished - Oct 2021

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 10 - Reduced Inequalities
      SDG 10 Reduced Inequalities

    Keywords

    • Australia
    • Bioeconomy
    • Biotechnology
    • DDB
    • Investor return
    • Performance

    Fingerprint

    Dive into the research topics of 'Australian Biotechnology: A 10-Year Study of Investor Performance'. Together they form a unique fingerprint.

    Cite this